AbCellera Investor Conference Presentation Deck
JPM HEALTHCARE CONFERENCE 2024
COPYRIGHT © ABCELLERA
8
OUR PIPELINE - ABCL575
ABCL575 is
a potential
best-in-class and
second-in-class
antibody therapy
for the treatment
of atopic dermatitis.
1. Croft M, et al. (2009) Immunol Rev. 229(1):173-91.
2. https://clinical trials.gov/search?intr-Amlitelimab
3. https://clinical trials.gov/search?intr-IMG-007
4. https://clinicaltrials.gov/search?intr-%20SAR-442970
Molecule
Status
Target
MOA
Indication
Therapeutic Area
Market
Opportunity
Potential
Differentiation
Summary
ABCL575
IND-enabling studies (Preclinical)
OX40 ligand (OX40L)
Blocking and non-depleting
Atopic dermatitis (AD)
Other indications in autoimmunity and inflammation
Immunology & inflammation
●
●
$17B by 2032*
ABCL575 has been designed with potency, pharmacokinetics,
and developability to enable less frequent dosing, which
provides a potential for differentiation.
Targeting OX40L has the potential to address a broad
range of inflammatory conditions and autoimmune diseases,
some of which include colitis/inflammatory bowel disease
(IBD), asthma/atopy, and diabetes¹.
OX40L blocking is currently under investigation for atopic
dermatitis², asthma², alopecia areata³, hidradenitis
suppurativa (HS)4.
*Source: IQVIAView entire presentation